country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-116791

Copy Link Print Information

Calanolide A

Calanolide A is an antioxidant that was initially thought to be produced by neuroblastoma cells but was later detected as a contaminant in the cell culture medium with no clear biological activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 142632-32-4
Fòrmula: C₂₂H₂₆O₅
Peso molecular:370.44

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (272 KB)

Calanolide A Chemical Structure

No. CAS: 142632-32-4

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- Ensayo clínico
Chemical Information
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Calanolide A is an antioxidant that was initially thought to be produced by neuroblastoma cells but was later detected as a contaminant in the cell culture medium with no clear biological activity.

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	EC₅₀	0.267 μM Compound: (+)-1	Anti-HIV activity against HIV-I RFII strain in CEM cell line Anti-HIV activity against HIV-I RFII strain in CEM cell line	[PMID: 8632437]
CCRF-CEM	IC₅₀	22.96 μM Compound: (+)-1	Anti-HIV activity against HIV-I RFII strain in CEM cell line Anti-HIV activity against HIV-I RFII strain in CEM cell line	[PMID: 8632437]
CEM-SS	EC₅₀	0.2 μM Compound: (+)-Calanolide A	Antiviral activity against HIV1 RF in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 RF in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 11430019]
CEM-SS	EC₅₀	0.08 μM Compound: 1	Inhibition of HIV-1 replication in CEM-SS human lymphoblastoid cells in vitro Inhibition of HIV-1 replication in CEM-SS human lymphoblastoid cells in vitro	[PMID: 1379639]
CEM-SS	EC₅₀	0.1 μM Compound: 1	Potency to inhibit HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication. Potency to inhibit HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication.	[PMID: 1379639]
CEM-SS	IC₅₀	20 μM Compound: 1	Concentration inhibiting HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication. Concentration inhibiting HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication.	[PMID: 1379639]
CEM-SS	ED₅₀	0.31 μM Compound: calanolide A	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 15217281]
CEM-SS	EC₅₀	0.18 μM Compound: 1	Using the XTT assay for cell viability, effective concentration to protect human lymphoblastoid CEM-SS cells from the cytopathic effects of HIV-1 (RF strain) was determined Using the XTT assay for cell viability, effective concentration to protect human lymphoblastoid CEM-SS cells from the cytopathic effects of HIV-1 (RF strain) was determined	[PMID: 8893846]
CEM-SS	IC₅₀	7.3 μM Compound: 1	Using the XTT assay for cell viability, inhibitory concentration to protect human lymphoblastoid CEM-SS cells from the cytopathic effects of HIV-1 (RF strain) was determined Using the XTT assay for cell viability, inhibitory concentration to protect human lymphoblastoid CEM-SS cells from the cytopathic effects of HIV-1 (RF strain) was determined	[PMID: 8893846]
CEM-SS	IC₅₀	23 μM Compound: (+)7	Antiviral activity against HIV-1 determined by concentration which resulted in cytotoxicity of 50% of CEM-SS cell population relative to drug-free controls Antiviral activity against HIV-1 determined by concentration which resulted in cytotoxicity of 50% of CEM-SS cell population relative to drug-free controls	[PMID: 9083491]
CEM-SS	EC₅₀	0.14 μM Compound: (+)-Calanolide A	Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells	[PMID: 9873509]
MT2	EC₅₀	0.027 μM Compound: (+)-1	Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line	[PMID: 8632437]
MT2	EC₅₀	0.053 μM Compound: (+)-1	Anti-HIV activity against HIV-I IIIB strain in MT2 cell line Anti-HIV activity against HIV-I IIIB strain in MT2 cell line	[PMID: 8632437]
MT2	EC₅₀	0.107 μM Compound: (+)-1	Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line	[PMID: 8632437]
MT2	EC₅₀	0.427 μM Compound: (+)-1	Anti-HIV activity against HIV-I A17 strain in MT2 cell line Anti-HIV activity against HIV-I A17 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	14.8 μM Compound: (+)-1	Anti-HIV activity against HIV-I IIIB strain in MT2 cell line Anti-HIV activity against HIV-I IIIB strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	6.99 μM Compound: (+)-1	Anti-HIV activity against HIV-I A17 strain in MT2 cell line Anti-HIV activity against HIV-I A17 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	7.15 μM Compound: (+)-1	Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line	[PMID: 8632437]
MT2	IC₅₀	7.17 μM Compound: (+)-1	Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line	[PMID: 8632437]
Raji	IC₅₀	290 molar ratio Compound: 1	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation after 48 hrs relative to control Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation after 48 hrs relative to control	[PMID: 12662094]

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 142632-32-4
Peso molecular 370.44
Fòrmula C₂₂H₂₆O₅
SMILES

CCCC(C1=C(O2)C3=C(O[C@@H]([C@H]([C@@H]3O)C)C)C4=C1OC(C)(C=C4)C)=CC2=O
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (272 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Concise synthesis of anti-HIV-1 active (+)-inophyllum B and (+)-calanolide A by application of (-)-quinine-catalyzed intramolecular oxo-Michael addition

[2]. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto